Akari CEO quits amid false data and report scandal

31 May 2017

A cloud is hanging over UK-registered biotech Akari Therapeutics (Nasdaq: AKTX) after inaccuracies came to light in a trial comparing its lead product to a rival drug and questions arose over the role of its chief executive in a related report.

Gur Roshwalb, who was placed on administrative leave while a review of what role he had played in the report issued by Edison Investment Research was undertaken, has stepped down after the investigation found that he had reviewed and approved the report, contravening company policy.

"The company has determined that the previously reported interim analysis of the ongoing Phase II PNH trial of Coversin, as stated in the release, was inaccurate with respect to one of five patients"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK